U.S. markets close in 28 minutes
  • S&P 500

    3,772.78
    -22.76 (-0.60%)
     
  • Dow 30

    30,860.39
    -131.13 (-0.42%)
     
  • Nasdaq

    13,014.42
    -98.22 (-0.75%)
     
  • Russell 2000

    2,131.17
    -24.18 (-1.12%)
     
  • Crude Oil

    52.24
    -1.33 (-2.48%)
     
  • Gold

    1,826.00
    -25.40 (-1.37%)
     
  • Silver

    24.79
    -1.01 (-3.92%)
     
  • EUR/USD

    1.2085
    -0.0071 (-0.58%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • GBP/USD

    1.3581
    -0.0110 (-0.81%)
     
  • USD/JPY

    103.8640
    +0.0480 (+0.05%)
     
  • BTC-USD

    35,240.44
    -2,598.21 (-6.87%)
     
  • CMC Crypto 200

    674.54
    -60.60 (-8.24%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,519.18
    -179.08 (-0.62%)
     

Recap: LivaNova Q3 Earnings

Benzinga Insights
·1 min read

 

Shares of LivaNova (NASDAQ:LIVN) were unchanged after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 54.76% year over year to $0.38, which beat the estimate of $0.21.

Revenue of $240,100,000 declined by 10.61% year over year, which beat the estimate of $218,550,000.

Outlook

The upcoming fiscal year's EPS expected to be between $1.15 and $1.35.

The upcoming fiscal year's revenue expected to be between $900,000,000 and $1,008,000,000.

How To Listen To The Conference Call

Date: Oct 29, 2020

View more earnings on LIVN

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/ra82i375

Technicals

Company's 52-week high was at $85.30

52-week low: $33.40

Price action over last quarter: Up 0.73%

Company Description

U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.